Invention Grant
- Patent Title: PD-L1 antibodies
-
Application No.: US15239959Application Date: 2016-08-18
-
Publication No.: US10214586B2Publication Date: 2019-02-26
- Inventor: Dale Lincoln Ludwig , Marshall Davenport Snavely , Yiwen Li , Juqun Shen , Vera Molkenthin
- Applicant: Eli Lilly and Company
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Robert Brian Johnson; Margaret M. Tomaska
- Main IPC: C07K16/28
- IPC: C07K16/28 ; A61K39/395 ; A61K45/06 ; A61K39/00
Abstract:
The present invention relates to antibodies that bind human programmed cell death 1 ligand 1 (PD-L1), and may be useful for treating solid and hematological tumors alone and in combination with chemotherapy and other cancer therapeutics.
Public/Granted literature
- US20170058033A1 PD-L1 Antibodies Public/Granted day:2017-03-02
Information query
